Prolonging the Response by Low-dose Rituximab Maintenance Therapy in Immune Thrombocytopenia: a Randomized Placebo-controlled Trial - the PROLONG Trial
Latest Information Update: 30 May 2024
At a glance
- Drugs Rituximab (Primary) ; Dexamethasone
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Acronyms PROLONG
- 28 May 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 28 May 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 06 Nov 2023 Status changed from recruiting to active, no longer recruiting.